Ebata T, et al. - In this study, =the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct cancer was tested. Patients with resected bile duct cancer assigned to gemcitabine and observation groups were not significantly different in terms of the probability of survival.